Physician profile
Tracy Vo
NPI 1598708430
$10,439.64
in general payments reported to CMS, 2019-2025
48 companies · $2,725 in 2025
The $2,725 reported for 2025 was more than what 96% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,212 · 2020: $442 · 2021: $733 · 2022: $645 · 2023: $1,938 · 2024: $1,745 · 2025: $2,725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,109 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,109.07 |
| Education | $298.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,071.90 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,058.59 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $879.74 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $872.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $786.49 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $669.92 | 2019-2025 | Evenity, Nplate, Repatha |
| Abbvie INC. | $509.95 | 2021-2025 | Vraylar, Synthroid, Qulipta |
| Janssen Pharmaceuticals, INC | $391.94 | 2019-2024 | Xarelto |
| Lundbeck LLC | $360.05 | 2023-2025 | Rexulti, Vyepti |
| Sanofi-Aventis U.S. LLC | $350.57 | 2019-2020 | |
| Pfizer INC. | $325.32 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $263.62 | 2019-2023 | Seglentis, Livalo |
| Merck Sharp & Dohme LLC | $239.45 | 2019-2023 | Belsomra |
| Novartis Pharmaceuticals Corporation | $207.13 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $201.71 | 2023-2025 | Rexulti |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.